Zimmer Biomet logged a -0.1% change during today's afternoon session, and is now trading at a price of $124.89 per share. The S&P 500 index moved 0.2% and the Nasdaq posted a -0.0% change. ZBH's trading volume is 247,027 compared to the stock's average volume of 1,246,544.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The large-cap Healthcare company has 19,500 full time employees and is based in Warsaw, IN. Zimmer Biomet has returned a 0.8% dividend yield over the last 12 months.
Zimmer biomet Is Likely Overvalued:
Compared to the Healthcare sector's average of 13.21, Zimmer Biomet has a trailing twelve month price to earnings (P/E) ratio of -186.1 and, based on its Eps guidance of 8.73, an expected P/E ratio of 14.3. The firm's price to earnings growth (PEG) is 2.35, which indicates that it is overvalued in terms of its expected rate of earnings growth. Furthermore, Zimmer Biomet's price to book (P/B) ratio is 2.1 compared to its sector average of 4.07.
There is Mixed market sentiment About Zimmer Biomet:
22 analysts are following Zimmer Biomet and have set target prices ranging from $95 to $145 per share. On average, they have given the company a rating of hold. At today's prices, ZBH is trading 0.68% away from its average analyst target price of $124.05 per share, implying an analyst consensus of little upside potential for the stock. The company has a very low short interest since 1.5% of the company's shares are tied to short positions. Institutions own 92.0% of Zimmer Biomet's shares, while the insider ownership rate stands at 0.07%. The biggest shareholder is Vanguard Group, Inc. (The) with a 11.24% stake in the company worth approximately $2,476,611,423.00.
